what is the difference between compounded glp 1 and wegovy semaglutide vs. Decoding GLP-1 Weight Loss Medications

According to new data from Worldpanel by Numerator, 6.3% of households in Great Britain now include at least one person currently using a GLP-1 medication in 2026, up sharply from 4.1% in 2025 and 2.3% in 2024

Newer 5-HT4 agonists

Discussing your baseline metabolic biomarkers, genetic context, medication history, and health goals helps your provider select the formulation and dose most likely to be effective and tolerable for your specific situation

Nausea-Friendly Meals

A systematic review pooling data from 27,617 patients found that semaglutide use lowered MACE risk by 19% overall (RR 0.81)

According to Holst this result was especially encouraging